medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20138875; this version posted June 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Article Summary Line: In one of the areas of first expansion of the epidemic in Italy IgG seroprevalence for SARS-CoV-2 increases with age, possibly suggesting age related differences in susceptibility to infection.

Running Title: Seroprevalence screening in Castiglione D'Adda.

Keywords: mass screening, seroprevalence, SARS-CoV-2, COVID-19

Title: Seroprevalence of SARS-CoV-2 IgG significantly varies with age: results from a mass population screening (SARS-2-SCREEN-CdA)

Authors: Gabriele Pagani[1,2], Federico Conti[1,2], Andrea Giacomelli[1,2], Dario Bernacchia[1,2], Rossana Rondanin[3], Andrea Prina[3], Vittore Scolari[4], Cecilia Eugenia Gandolfi[1], Silvana Castaldi[1,5], Giuseppe Marano[1], Cosimo Ottomano[6], Patrizia Boracchi[1], Elia Biganzoli[1*], Massimo Galli[1,2*].

Affiliations:

1: Università degli Studi di Milano, Italy

2: ASST FBF-Sacco, Milano, Italy

3: Medispa s.r.l.

4: Institut Curie-PSL Research University, CNRS, Sorbonne Université, UMR3664, F-75005, Paris, France.

5: Fondazione IRCCS Ca' Granda Ospedale Maggiore policlinico di Milano, Italy

6: Synlab s.p.a.

*****Equally contributing Authors

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20138875; this version posted June 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract – 48 words

Castiglione D'Adda is one of the towns earlier and more severely affected by the SARS-CoV-2 epidemic in Lombardy. In a mass screening involving 4174 out of about 4550 total inhabits, significant age-related differences in anti SARS-CoV-2 IgG seroprevalence were found, with the lowest prevalence in the youngest inhabitants.

Text – 691 words

Background and Methods

Coronavirus Induced Disease 2019 (COVID-19) is caused by a novel *betacoronavirus* which was first identified in China and denominated SARS-CoV-2 (Severe Acute Respiratory Sindrome Coronavirus 2) [1]. Italy was the first European country that suffered a wide spread of the infection, which caused hundreds of thousands of cases [2].

The municipality of Castiglione d'Adda, a town of about 4550 inhabitants, has been heavily affected by SARS-CoV-2 infection since the earliest stages of the epidemic and subjected to movement restrictions since February 23rd, 2020. As of June 21, 2020, 184 confirmed cases of COVID-19 were reported, the large majority of which requiring hospitalization, accounting for about 4% of the total population. At the same time, 76 deaths were officially attributed to COVID-19, with an overall population mortality of 1.7%. During the epidemic, testing was restricted to severely symptomatic cases. Consequently, the true extent of the SARS-CoV-2 infection remains unknown. In this study, the entire population of Castiglione D'Adda was invited to perform a lateral-flow immunocromatographic tests on capillary blood (Prima Lab, Switzerland). Moreover, a random sample of 562 subjects (stratified per sex and age) and all subjects tested positive to the rapid test were invited to undergo confirmatory tests by chemiluminescent method on venipuncture drawn blood (CLIA, IgG anti-SARS-CoV-2, Abbott, USA) and SARS-CoV-2 PCR on NPS [3].

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20138875; this version posted June 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The analysis of IgG prevalence in the different age groups was performed by logistic regression models with response variable equal to 1 for positive IgG results, and 0 for negative IgG results. Age and gender were included as independent variables. Results were reported in terms of estimated probabilities of being positive to IgG test as a function of age, with respective 95% confidence intervals.

Results and Discussion

The analysis was based on 509 subjects of the random sample with available results. The overall seroprevalence found in the tested sample was 22.6% (95% confidence interval 17.2- 29.1). A significant effect of age was found ($p<0.0001$) while no significant association emerged between IgG results and gender ($p=0.2560$). The possible existence of a non-linear effect of age was tested by including spline polynomials, without significant results ($p=0.9078$). Furthermore, an age/gender interaction effect did not result significant ($p=0.5199$). Estimates of probabilities of being positive to IgG test, from a model including only age as independent variable, are reported in Fig.1 and Tab. 1.

Since the early phases of the pandemic, advanced age was identified as an independent predictor for severe disease and worse outcomes [4]. Beside this, it remains unclear if the limited number of cases reported in children [5] is due to a milder course of disease, with a larger percentage of asymptomatic cases, or to a lower susceptibility to infection, as our results seem to suggest. Different ACE2 expression according to age have been postulated to explain clinical expression and susceptibility to the infection. In particular, a higher expression of ACE2 in lung tissues in advanced age groups had been speculated [6, 7]. Moreover, a variable susceptibility to other coronavirus such as HCoV-NL63, which also use ACE2 as cell receptor in humans, in different age groups, has been also reported in different age groups [8].

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20138875; this version posted June 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Another possible explanation may be that an asymptomatic/pauci-symptomatic infection, more common in younger subjects, could elicit a less marked, or transient, antibody response, as already found in the closely related Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [9].

A possible confounding factor in our findings could be related to social distancing measures: schools of any grade were among the first institutions to be closed in Italy, starting from the 5th of March. This could have led to a lower exposure to the infection in children in pre-scholar and scholar age groups.

In conclusion, our findings suggest that IgG seroprevalence for SARS-CoV-2 increases with increasing age and these data suggest a lower susceptibility to infection in the lower age groups. These findings have important implications in epidemiology and public health, particularly in designing future population screenings, and could be an important contribution in the re-opening process, especially considered that more than three-fourths of the population could be still susceptible to SARS-CoV-2 infection, even in an area of initially unrestricted viral circulation.

Conflict of interests

The authors declare no conflicts of interest.

Acknowledgments

MG, GP, FC, DB, AG, RR and EB defined the study protocol. GP drafted a first version of the manuscript, which was then revised and integrated by MG, EB, AG, CEG and SC. EB, PB and GM analyzed the data. All authors approved the final version of the manuscript.

We also acknowledge the non-conditioning economical support from CISOM (Corpo Italiano di Soccorso dell'Ordine di Malta), Banca Mediolanum s.p.a., Fondazione Rava and FC Internazionale Milano.

The study was approved by University of Milan's Ethical Committee.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20138875; this version posted June 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Author Bio

Gabriele Pagani is an Infectious Diseases resident at Luigi Sacco Hospital (Milano, Italy), currently ending his last year of residency. His primary interests are tropical and traveler diseases and anthropo-zoonoses, particularly in One Health and Global Health perspectives.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20138875; this version posted June 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References:

[1] Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; 382: 727–733.

[2] EpiCentro. Coronavirus | Istituto Superiore di Sanità, https://www.epicentro.iss.it/coronavirus/ (accessed 29 May 2020).

[3] Pagani G, Bernacchia D, Conti F, et al. Dynamics of the SARS-CoV-2 epidemic in the earliest-affected areas in Italy: 1 Mass screening for SARS-CoV-2 serological positivity (SARS-2-SCREEN). *medRxiv* 2020; 2020.06.06.20124081.

[4] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020; 395: 507–513.

[5] Lee P-I, Hu Y-L, Chen P-Y, et al. Are children less susceptible to COVID-19? *Journal of Microbiology, Immunology and Infection* 2020; 53: 371–372.

[6] Li Y, Zhou W, Yang L, et al. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. *Pharmacological Research* 2020; 157: 104833.

[7] Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19). *The Journal of Pathology*; n/a. DOI: 10.1002/path.5471.

[8] Huang S-H, Su M-C, Tien N, et al. Epidemiology of human coronavirus NL63 infection among hospitalized patients with pneumonia in Taiwan. *Journal of Microbiology, Immunology and Infection* 2017; 50: 763–770.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20138875; this version posted June 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

[9] Choe PG, Perera RAPM, Park WB, et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. *Emerg Infect Dis* 2017; 23: 1079–1084.

Corresponding author:

Gabriele Pagani

Infectious Diseases department, III Division

ASST FBF-Sacco

Via G.B. Grassi 74, 20157, Milano

gabriele.pagani@unimi.it

02 3904 2591

Tab.1 Estimates of the probability of IgG positivity for age interval of five years

C.I. = confidence interval

Fig.1: Estimated probability of IgG positivity as a function of age

Solid line: estimates, dashed lines: 95% confidence intervals.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20138875; this version posted June 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

AGE	PROBABILITY (95% C.I.)	AGE	PROBABILITY (95% C.I.)
5	9.1% (4.4%, 13.8%)	**50**	22.3% (18.5%, 26.0%)
10	10.1% (5.4%, 14.8%)	**55**	24.3% (20.4%, 28.3%)
15	11.2% (6.6%, 15.9%)	**60**	26.6% (22.2%, 30.9%)
20	12.5% (7.9%, 17.0%)	**65**	28.9% (23.8%, 33.9%)
25	13.8% (9.3%, 18.2%)	**70**	31.3% (25.4%, 37.3%)
30	15.2% (11.0%, 19.5%)	**75**	33.9% (26.8%, 41.0%)
35	16.8% (12.7%, 20.9%)	**80**	36.6% (28.3%, 44.9%)
40	18.5% (14.6%, 22.4%)	**85**	39.3% (29.7%, 48.9%)
45	20.3% (16.6%, 24.0%)	**90**	42.1% (31.1%, 53.1%)


60
50
40
30
20
10
0
Probability (%)
0
20
40
60
80
Age (Years)